Aveanna Healthcare (NASDAQ:AVAH) Given New $11.00 Price Target at Barclays

by · The Markets Daily

Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) had its price target raised by research analysts at Barclays from $9.00 to $11.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 13.55% from the stock’s current price.

Several other equities analysts also recently weighed in on AVAH. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 20th. Jefferies Financial Group raised their price objective on shares of Aveanna Healthcare from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Truist Financial upped their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a report on Friday, November 7th. William Blair began coverage on Aveanna Healthcare in a report on Monday, December 8th. They set an “outperform” rating on the stock. Finally, Raymond James Financial restated an “outperform” rating and issued a $13.00 price objective on shares of Aveanna Healthcare in a research report on Friday, December 5th. Five equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $11.06.

Read Our Latest Analysis on Aveanna Healthcare

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock traded down $0.07 during trading on Friday, reaching $9.69. The company had a trading volume of 268,089 shares, compared to its average volume of 1,387,896. The firm’s 50-day simple moving average is $8.82 and its 200 day simple moving average is $7.73. Aveanna Healthcare has a 52 week low of $3.67 and a 52 week high of $10.32. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of 26.94 and a beta of 2.06.

Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. Aveanna Healthcare had a negative return on equity of 143.55% and a net margin of 3.29%.The business had revenue of $621.94 million during the quarter, compared to analysts’ expectations of $578.57 million. Sell-side analysts forecast that Aveanna Healthcare will post -0.06 earnings per share for the current fiscal year.

Insider Activity at Aveanna Healthcare

In other Aveanna Healthcare news, CEO Jeff Shaner sold 29,357 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.85, for a total transaction of $230,452.45. Following the completion of the transaction, the chief executive officer owned 2,394,179 shares in the company, valued at $18,794,305.15. This trade represents a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Edwin C. Reisz sold 17,613 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $7.85, for a total transaction of $138,262.05. Following the sale, the insider owned 1,321,114 shares in the company, valued at $10,370,744.90. This represents a 1.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 32,857,606 shares of company stock valued at $295,491,307 over the last quarter. 7.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aveanna Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of AVAH. Summit Partners L P purchased a new stake in Aveanna Healthcare in the 2nd quarter valued at about $50,477,000. AustralianSuper Pty Ltd purchased a new position in shares of Aveanna Healthcare during the third quarter worth approximately $15,743,000. Vanguard Group Inc. raised its stake in shares of Aveanna Healthcare by 34.7% during the third quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company’s stock valued at $35,850,000 after acquiring an additional 1,041,324 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of Aveanna Healthcare in the third quarter valued at approximately $7,922,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Aveanna Healthcare in the third quarter valued at approximately $7,356,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

(Get Free Report)

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.

Recommended Stories